ResearcherHarvard UniversityActive in the last 2 years
Soldano Ferrone
Matched on ORCID iD 0000-0003-2900-8834; OpenAlex author ID A5028669896; NIH RePORTER profile ID 6618381. Sources: OpenAlex.
Their work
- Papers
- 8
- Trials
- 0
- Grants
- 4
- Labs led
- 1
- Collaborators
- 38
2014: 1 grant · 2015: 1 grant · 2016: none · 2017: 2 papers · 2018: 2 papers · 2019: 1 grant · 2020: 1 paper · 2021: 1 paper, 1 grant · 2022: none · 2023: 1 paper · 2024: 1 paper
Papers 8
- Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.216713↗
- Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy. Co-author DOI 10.1016/j.drudis.2022.103434↗
- Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. Co-author DOI 10.1093/jnci/djaa073↗
- A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-020-02414-9↗
- 212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. Co-author DOI 10.1016/j.nucmedbio.2017.12.004↗
- Corrigendum to '212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models' [Nucl Med Biol 58 (2018) 67-73]. Co-author DOI 10.1016/j.nucmedbio.2018.03.004↗
- A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. Co-author DOI 10.1016/j.canlet.2017.08.028↗
- Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.16841↗
Grants 4
- B7-H3 CAR T cell-based immunotherapy combined with Losartan to counteract desmoplasia for the treatment of Pancreatic Ductal Adenocarcinoma (PDAC) R03CA249542↗
- IL-15 TRiKES-based specific immunotherapy of pancreatic ductal adenocarcinoma R03CA231766↗
- Therapy of pancreatic cancer with 212Pb-labeled B7-H3 specific Ab and LDE225 R21CA173120↗
- Grp94 targeted therapy for pancreatic ductal adenocarcinoma R21CA164756↗
Closest collaborators
The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Cristina Rosa Ferrone · 4 shared papers, 3 shared grants, 2014–2021 · strength 1.44
- Grant B7-H3 CAR T cell-based immunotherapy combined with Losartan to counteract desmoplasia for the treatment of Pancreatic D… R03CA249542↗
- Grant IL-15 TRiKES-based specific immunotherapy of pancreatic ductal adenocarcinoma R03CA231766↗
- Grant Grp94 targeted therapy for pancreatic ductal adenocarcinoma R21CA164756↗
- Cristina R. Ferrone · 3 shared papers, 2018–2024 · strength 0.52
- Paper Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy. DOI 10.1016/j.drudis.2022.103434↗
- Paper Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2024.216713↗
- Paper 212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. DOI 10.1016/j.nucmedbio.2017.12.004↗
- Lei Cai · 4 shared papers, 2017–2024 · strength 0.39
- Paper Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2024.216713↗
- Paper Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. DOI 10.1093/jnci/djaa073↗
- Paper Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. DOI 10.18632/oncotarget.16841↗
- Theodoros P. Michelakos · 4 shared papers, 2017–2024 · strength 0.39
- Paper Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2024.216713↗
- Paper Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. DOI 10.1093/jnci/djaa073↗
- Paper Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. DOI 10.18632/oncotarget.16841↗
- Donald J Buchsbaum · 2 shared papers, 1 shared grant, 2015–2018 · strength 0.38
- Grant Therapy of pancreatic cancer with 212Pb-labeled B7-H3 specific Ab and LDE225 R21CA173120↗
- Paper 212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. DOI 10.1016/j.nucmedbio.2017.12.004↗
- Paper Corrigendum to '212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models' [Nucl Med Biol 58… DOI 10.1016/j.nucmedbio.2018.03.004↗
- Xinhui Wang · 4 shared papers, 2017–2024 · strength 0.38
- Paper Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2024.216713↗
- Paper A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal aden… DOI 10.1186/s12967-020-02414-9↗
- Paper Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. DOI 10.18632/oncotarget.16841↗
- Vikram Deshpande · 3 shared papers, 2017–2024 · strength 0.33
- Paper Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2024.216713↗
- Paper Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. DOI 10.1093/jnci/djaa073↗
- Paper Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. DOI 10.18632/oncotarget.16841↗
- David Tsai Ting · 2 shared papers, 2021–2024 · strength 0.27
- Ahmed O. Elzoghby · 1 shared paper, 2023 · strength 0.26
- Mahmoud Lotfi Nasr · 1 shared paper, 2023 · strength 0.26
- Tomohiro Kurokawa · 2 shared papers, 2020–2021 · strength 0.19
- Paper Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. DOI 10.1093/jnci/djaa073↗
- Paper A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal aden… DOI 10.1186/s12967-020-02414-9↗
- Kurt R. Zinn · 2 shared papers, 2018 · strength 0.17
- Benjamin B. Kasten · 2 shared papers, 2018 · strength 0.17
- Yurie Sekigami · 1 shared paper, 2024 · strength 0.17
- Paul A. Moore · 1 shared paper, 2024 · strength 0.17
- Marco Ventin · 1 shared paper, 2024 · strength 0.17
- Giulia Cattaneo · 1 shared paper, 2024 · strength 0.17
- Nabeel M. Bardeesy · 1 shared paper, 2024 · strength 0.17
- Gong Zhang · 2 shared papers, 2017–2020 · strength 0.16
- Paper A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal aden… DOI 10.1186/s12967-020-02414-9↗
- Paper Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. DOI 10.18632/oncotarget.16841↗
- Theodore Sunki Hong · 2 shared papers, 2017–2021 · strength 0.15
- Keith D. Lillemoe · 2 shared papers, 2017–2021 · strength 0.15
- Carlos Fernández-del Castillo · 1 shared paper, 2021 · strength 0.10
- Azfar Neyaz · 1 shared paper, 2021 · strength 0.10
- Andrew Louis Warshaw · 1 shared paper, 2021 · strength 0.10
- David P. Ryan · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.